

**Albert A. Rizzo MD, FACP,  
FCCP, FAASM**

Chief Medical Officer  
American Lung Association  
Chicago IL

Clinical Assistant Professor of Medicine  
Sidney Kimmel Medical College  
Thomas Jefferson University, Philadelphia PA

Pulmonary/Sleep Staff Physician  
Christiana Care Health System, Newark DE



Dr. Albert A. Rizzo is the Chief Medical Officer for the American Lung Association and practices pulmonary/sleep medicine at the Christiana Care Health System in Newark, Delaware as a member of Christiana Care Pulmonary Associates. He is board-certified in internal medicine, pulmonary, critical care and sleep medicine and is a Clinical Assistant Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia where he obtained his medical degree(1978) and completed his residency in Internal Medicine (1978-1981) He received his specialty training at Georgetown University Hospital in Wash DC. (1981-1983) He is a member of the American Thoracic Society, a Fellow of the American College of Chest Physicians and the American College of Physicians and the American Association of Sleep Medicine an a Diplomat of the American Board of Sleep Medicine.

His out-patient practice covers general pulmonary and sleep medicine disorders and includes a strong interest in asthma, COPD, pulmonary fibrosis, pulmonary rehabilitation, lung cancer and obstructive sleep apnea. He has held administrative duties at Christiana Care Health System that included Pulmonary Section Chief, Medical Director of E-ICU, Medical Director of Pulmonary Rehabilitation and Medical Director of the School of Respiratory Therapy. He relinquished these roles as he took on the responsibilities of the Chief Medical Officer for the American Lung Association in November 2018.. During his thirty-plus years in practice, he also served as the Principal Investigator for over 30 clinical trials in the fields of asthma, COPD, pulmonary fibrosis, pneumonia and sleep apnea.

Dr. Rizzo had been a volunteer with the American Lung Association (ALA) since 1984 at both the local, regional and national level. He served as Chairman of the National Board of Directors of the American Lung Association, 2011-2012. As a result of his service and achievements, he was awarded the Will Ross Medal for significant contribution to the prevention and control of lung disease in June 2015. He continued to serve as the senior Medical Advisor to the national office of the American Lung Association until being appointed the Chief Medical Officer for the organization in November 2018. In this role he collaborates with external partners to connect

shared priorities and facilitate opportunities related to the American Lung Association's mission of promoting lung health and preventing lung disease through research, advocacy and education. He is especially involved with working on a level with the medical leadership of those external partners. In this role, Dr. Rizzo is currently the American Lung Association's leading medical authority. He is their key medical advisor and leading media spokesperson.

As a result of his involvement with the ALA, Dr. Rizzo has had the opportunity to educate both patients and the public as well as fellow professionals about the importance of preventive care and healthy lifestyles (particularly the role of cigarette smoking cessation) with regard to preserving lung function over the years. In his volunteer leadership roles he has testified before Congress on behalf of advancing lung disease research through funding of NIH and has lectured at American Lung Association meetings throughout the country. In addition to smoking cessation, tobacco control and air quality, his topics include specific disease states such as COPD, Asthma, Sleep Apnea, and Lung Cancer. The importance of recognizing and trying to eliminate some of the health care disparities that often involve these diseases is one of his concerns.

**Albert A. Rizzo, M.D. FACP, FCCP, D'ABSM**

Chief Medical Officer  
American Lung Association  
Chicago IL

Clinical Assistant Professor of Medicine Sidney Kimmel Medical College  
Thomas Jefferson University, Philadelphia PA

Pulmonary/Sleep Staff Physician  
Christiana Care Health System, Newark DE  
Office: Suite 220, Medical Arts Pavilion One, 4745 Ogletown-Stanton Road

**PERSONAL:**

Date of Birth:	06/22/1952	Location:	Williamsport, PA
Citizenship:	United States		
Marital Status:	Married	Wife:	Janet Ann Tighe

**EDUCATION:**

Undergraduate:	Johns Hopkins University Baltimore, M.D. B.A. Natural Sciences	1970-1974
Graduate:	Thomas Jefferson University Jefferson Medical College Philadelphia, PA	1974-1978

**POST-GRADUATE TRAINING:**

Internship and Residency:	Thomas Jefferson University Philadelphia, PA <i>Internal Medicine</i>	1978-1981
Fellowship:	Georgetown University Hospital Washington, DC <i>Pulmonary Medicine</i>	1981-1983
Preceptorship:	Kennedy Hospital RWJ Medical System <i>Sleep Medicine</i>	1999-2001

**CERTIFICATIONS:**

National Board of Medical Examiners	1979
American Board of Internal Medicine	1981-Present

Pulmonary Medicine	1984-Present
--------------------	--------------

**CERTIFICATIONS: continued**

Critical Care	1987-2020
---------------	-----------

Sleep Medicine	2007-2018
American Board of Sleep Medicine	04/2003-Present

**LICENSURE:**

Pennsylvania	MD-022283-E	1978 Inactive
Maryland	D0029476	1983 -Expired
Delaware	C100002286	1983 active
New Jersey	58078	1992-Expired

**HONORS/AWARDS:**

Phi Beta Kappa	Johns Hopkins University	1974
Alpha Omega Alpha	Jefferson Medical College	1977
American Lung Association		
John Janvier Black, M.D. Award for Community Service		1992
Volunteer Excellence Award in Program Innovation		1999
Volunteer Excellence Award 2000 Nominee		2000
National Volunteer of the Week		Sept 2004
American Respiratory Care Foundation		1995
Open Forum Award: "Best New Author"		
"Who's Who" 2001 Edition		2001
Life Member National Registry		
Outstanding Specialist Preceptor Award, Dept. of Family and Community Medicine, Christiana Care Health System		2000
ACCP Governor's Community Service Award Nominee		
Adopt-a-School Program: Asthma Initiative		
"Spacer Camp": Summer Camp for Asthmatic Children		
Delaware Asthma Consortium		
Physician Ambassador elected by nurses for Magnet Status		2003
Community Health Award- Delaware Society of Resp Care		Oct. 2004
Outstanding Clinician Award from the Delaware Thoracic Society		Mar. 2008
Will Ross Medal, highest award for service to the American Lung Assoc		June 2015

**HOSPITAL AFFILIATIONS:**

Christiana Care Health Services, Newark, DE		
Department of Medicine-Pulmonary/Critical Care Section		
Assistant		1983-1993
Associate		1993-2007
Chief		2007-2018
Department of Medicine-Pulmonary Section		2017-Present
St. Francis Hospital		1983-2011
Wilmington, DE		
Department of Medicine-Pulmonary Section		
Assistant		1983-1993
Associate		1993-2011

### **HOSPITAL AFFILIATIONS: continued**

Riverside Hospital Wilmington, DE Consultant Staff	1983-1988
University of Delaware Newark, DE Consultant Staff	1991-1992
Union Hospital Elkton, MD Department of Medicine-Pulmonary Section	2001-2004

### **ACADEMIC APPOINTMENTS:**

Jefferson Medical College Thomas Jefferson University Philadelphia, PA	Instructor in Medicine Clinical Assistant Professor of Medicine	1992-1996 1996-Present
--	--	---------------------------

### **PROFESSIONAL ORGANIZATIONS: PROFESSIONAL ORGANIZATIONS**

American College of Physicians	Associate Fellow	1991
American College of Chest Physicians	Fellow State Chapter Governorte	1982 1998-2002
American Thoracic Society		1983-Present
Delaware Thoracic Society	President-Elect/President	1997-2001
Delaware Medical Society		1983-Present
American Lung Association of Delaware	Board of Directors	1987-2008
Society of Critical Medicine		2000-2017
National Association of Inpatient Physicians	Charter Member	1998
Christiana Care Physician Organization	Board of Directors	2000-2002
TSSCVP	Physician Liaison	2000-2008
AACVPR	Professional Liaison Committee	2000-2003
American Association of Sleep Medicine		2000-Present

### **PROFESSIONAL AND COMMUNITY SERVICE:**

American Lung Association of Delaware		
President		1996-1998, 2002-2004
President-Elect		1994-1996, 2000-2001
Board of Directors		1987-2008
Medical Spokesperson—Sarcoid Support Group		1992-1995
Financial Development Committee		1992-1993
Long-Range Planning Committee		1995-2008
Annual Symposium Program Chairman “Perspectives in Pulmonary Care”		1990-2008
Delaware Asthma Consortium Chairman		1998-2004
Research Committee		1999-2004

**PROFESSIONAL AND COMMUNITY SERVICE: continued**

American Lung Association National Council	
Delegate Representative	2004-2006
American Lung Association Nationwide Assembly, Speaker	2008-2009
Speaker-elect of Nationwide Assembly	2007-2008
Chair, Advocacy Committee	2006-2008
Vice-Chair, Strategic Planning Committee	2007-2008
American Lung Association	
Chairman, National Board of Directors	2011-2012
Governance Committee Chairman	2012-2014
Chairman, Lung Cancer Expert Medical Advisory Panel	2013-Present
Senior Medical Advisor to the American Lung Association	2014-Present
Christiana Care Health Services (Formerly Medical Center of Delaware)	
Education Committee	1986-1990
Cardiovascular Surgery Quality Assurance Committee	1992-1994
Medical Director, Pulmonary Rehabilitation	1993-Present
Allied Health Resp Care Education Advisory Committee	1992-2018
Medical Director—Pulmonary Disease Management	2003-Present
COPD/Asthma/Pneumonia Care Guideline Development	
Discharge Planning Process for Pulmonary Disease	
Lung Cancer Health Improvement Team	2000-2006
Patient Safety Committee	2005
Pharmacy and Therapeutics Committee	2006-2011
Chief of Section: Pulmonary Medicine	2007-2018
Executive Committee Department of Medicine	2007-2018
Credentials Committee, Department of Medicine	2013-2018
Sleep Care, Inc.	
Medical Director (Wilmington and Bear, DE sites)	2001-2011
St. Francis Hospital	
Medical Director of Pulmonary Services for Select Specialty	2001-2007
State of Delaware	
Advisory Committee for Cancer Control	1987-1988
Pharmacy and Therapeutic Committee, Chairman	2005-2008
Creation of Preferred Drug List for DE Medicaid	
Appointed by Delaware Secretary of Health Human Services	
Drug Utilization Review Board – State of Delaware	2005-2008
Screening for Life – Lung Cancer Screening Committee	2014-Present
Delaware Telehealth Coalition	2013-2017
Mid-Atlantic Telehealth Resource Center (MATRC) Advisory Board	2015-2017
Medical Society of Delaware	
Publication & Editorial Committee	1992-1994
Environmental & Public Health Committee	1994-2001
Impact Delaware Coalition for Smoking or Health	
Medication Adherence Task Force Committee-Asthma	2000-2002
Asthma Clinical Guidelines Committee-Chairman	2001
Membership Committee	2001-2003
Health Hub Advisory Board	2018-Present
American College of Chest Physicians	
Governor of Delaware	1998-2002
Quality Insights of Delaware (Medicare QIO)	
Board of Directors	2004-2010
Quality Management Committee – Delaware Physicians Care Inc	2006-2010
Jefferson Medical School Alumni Association-Exec Committee	2005-2016

US COPD Coalition Board of Directors  
**CORPORATE AFFILIATIONS:**

2018-Present

Speakers' Bureau/Advisory Boards/Consultant

Astra-Zeneca	2009-Present
Glaxo Smith Kline	2001-2008
Boehringer Ingelheim Pharmaceutical	2004-2013, 2017-present
Aventis	2004-2006
Pfizer	2004-2010
Novartis	2007-Present
Forest	2011-2015
Genentech	2015- Present
Abbvie	2017-Present
Sunovion	2017-Present
Thermofisher	2016-Present
PMD HealthCare	2017-Present
Strados Laboratories	2018-Present
Persante Healthcare	2016-Present

**RESEARCH:**

1982 *Post-operative Pulmonary Complications in Patients Undergoing Gastric Partitioning-Incentive Spirometry versus Volume-Controlled IPPB*  
Georgetown University

1983 *The Effect of Weight Loss on CO<sub>2</sub> Rebreathing Tests in Patients Who Have Undergone Gastric Partitioning*  
Georgetown University

1993-1994 *Combivent Study*  
Boehringer-Ingelheim  
Principal Investigator

06/93-11/94 *Ned Cromil Sodium Inhalation Aerosol Clinical Study*  
In Conjunction with Fisons  
Sub-Investigator

12/93-05/94 *Combivent Inhalational Aerosol Clinical Study*  
Boehringer-Ingelheim Pharmaceuticals, Inc.  
Principal Investigator

03/95-08/95 *Trial to evaluate the feasibility and validation of measurements of elastase and markers of elastolytic activity in subjects with respiratory disease with mucus hypersecretion*  
Zeneca Pharmaceuticals, Wilmington, DE  
Principal Investigator

10/95-04/98 *A multicenter randomized double-blind placebo-controlled trial of zafirlukast (Accolate) in subjects with mild to moderate asthma*  
Zeneca Pharmaceuticals, Wilmington, DE Sub-Investigator

12/95-04/98 *A named patient safety study of Pulmicort (budesonide) Turbuhaler in severe asthmatic patients aged five and older.*  
Astra Pharmaceuticals, Westborough, MA  
Sub-Investigator

01/97-02/98 *An open-label, multicenter, non-comparative Phase II/III study of oral gatifloxacin in the treatment of atypical pneumonia.*  
Bristol-Myers Squibb, Wallingford, CT

Principal Investigator

**RESEARCH:** continued

- 01/97-05/97 *An open-label, multicenter, non-comparative study of oral gatifloxacin in the treatment of acute exacerbation of chronic bronchitis. (Also participated in the pharmacokinetic arm of the study.*  
Bristol-Myers Squibb, Wallingford, CT  
Principal Investigator
- 06/97-04/98 *A comparison of salmeterol versus theophylline versus salmeterol plus theophylline in COPD patients.*  
Glaxo Wellcome, Research Triangle Park, NC  
Sub-Investigator
- 06/97-05/98 *A randomized, double-blind, multicenter comparative study of gatifloxacin versus levofloxacin in the treatment of acute exacerbation of chronic bronchitis.*  
Bristol-Myers Squibb, Wallingford, CT  
Principal Investigator
- 03/98-03/99 *Follow up, pilot study of the infection-free interval following treatment of acute exacerbation of chronic bronchitis.*  
Bristol-Myers Squibb  
Principal Investigator
- 08/98-05/99 *A randomized double-blind, multicenter comparative study of gatifloxacin versus clarithromycin in the treatment of acute exacerbation of chronic bronchitis.*  
Bristol-Myers Squibb - #064  
Principal Investigator
- 08/99-07/00 *A randomized double-blind, multicenter comparative study of gatifloxacin versus azithromycin in the treatment of acute exacerbation of chronic bronchitis.*  
Bristol-Myers Squibb - #065  
Principal Investigator
- 11/99-06/00 *A randomized double-blind, double-dummy, multicenter parallel group study to assess the efficacy and safety of oral Augmentin-SR 2000/125 mg b.i.d. x 7 days versus oral clarithromycin 500 mg b.i.d. x 7 days in the treatment of acute exacerbation of chronic bronchitis.*  
SmithKline Beecham  
Principal Investigator
- 11/99-11-01 *Serum/Sputum Tumor Marker Assays*  
*Sample banking for research and development*  
Bayer SB00489  
Principal Investigator
- 10/00-06/04 Matkin and Johnson  
TENOR study #Q2196N  
Principal Investigator
- 04/01-08/02 Glaxo Wellcome  
SMART study #SLGA5011
- 09/01-07/02 Aventis TREAT study #3014A Principal Investigator



**RESEARCH:** continued

09/05-12/05	Aperon Biosystems-Observational Study of eNO in Asthma in School Age Children with Exacerbations Principal Investigator
09/05-01/07	Aventis Comparative Trial of Ketek vs Zithromax in AECB and CAP Principal Investigator
09/05-2007	The Role of CPAP treatment in Improving Cardiac Autonomic Neuropathy in Diabetic Patients with Obstructive Sleep Apnea In conjunction with Diabetes center Christiana Care Health Systems (Published in CHEST, Feb 2008)
10/06	Respironics: The Impact of BiPAP Auto SV on OSA and Complex Sleep Apnea
01/07-02/07	Aquavan, Sub-investigator Conscious sedation protocol for bronchoscopy
01/07-11/09	Astra Zeneca: AZ-D5896C00022 A 52-week, randomised, double-blind, parallel-group, multi-centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 µg x 2 actuations twice daily to budesonide HFA pMDI 160 µg x 2 actuations twice daily in adult and adolescent (≥12 years) African American subjects with asthma. Principal Investigator
01/07-05/11	Temple: Long – Term Oxygen Treatment Trial (LOTT)/NHLBI-HR-06-07
02/07-07/08	Novartis: QAB149B2335S A 26-week treatment, multicenter, randomized, doubleblind,double dummy, placebo-controlled, adaptive,seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 µg o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 µg b.i.d) and open label tiotropium (18 µg o.d.) as active controls. Principal Investigator
5/07-12/07	Novartis: NVA237A 2206 A randomized, double-blind, placebo controlled, parallel group, multi-center study to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). Principal Investigator
6/07-11/08	Genentech: Q3662g A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Xolair® in Subjects with Moderate to Severe Persistent Asthma Who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists. Principal Investigator
11/07-10/08	GlaxoSmithKline: Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD. Principal Investigator
03/08-08/08	Novartis: QAB149B2346 A 12-week treatment, multi-center, randomized, doubleblind, placebo controlled, parallel group study to assessthe efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructive pulmonary disease. Principal Investigator
04/08-04/09	Actelion: AC-052-419: An Open-Label, Multi-Center Study Employing a Targeted 6 MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling. Sub-Investigator
10/08-2012	Gilead: GS-US-231-0101 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF). Principal Investigator

**RESEARCH:** continued

- 11/08-12/09 Novartis: QAB149B2349 A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 µg o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50 µg b.i.d.) as an active comparator delivered via a DISKUS inhaler. Principal Investigator
- 01/09-09/09 Ception: Res-5-0010 An Efficacy and Safety Study of Reslizumab (CTx55700) Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation. Principal Investigator
- 04/09-2011 Forest: LAS-MD-35 Long-term safety of Aclidinium Bromide when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). Principal Investigator
- 06/09-10/09 Actelion: AC-063A301 A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary Arterial Hypertension
- 06/09-10/09 Actelion: AC-063A302 A Multicenter, Double-blind, Randomized Study Comparing the Safety and Tolerability of Iloprost Inhalation Solution Delivered by I-neb Utilizing Power Disc-15 to Power Disc-6 in Patients with Symptomatic Pulmonary Arterial Hypertension
- 12/09-2012 Novartis: CNVA237A2304 A 26-week treatment, randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease.
- 08/10-2013 Actelion: AC-065A302 A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension. Sub-Investigator
- 08/10-2013 Actelion: AC-065A303-OL Long-term single-arm open-label study, to assess the safety and tolerability of ACT-293987 in patients with pulmonary arterial hypertension. Sub-Investigator
- 09/10-2013 Boehringer: 205.452 A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler® Principal Investigator
- 01/11-2013 Actelion: AC-066A501 PROSPECT Registry (Registry to PROSPECTively Evaluate Use of Room Temperature Stable (RTS) Epoprostenol for Injection in Patients with Pulmonary Arterial Hypertension. Sub-Investigator
- 05/11-2013 Boehringer: 1199.32 A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) Principal Investigator
- 08/11-2013 Actelion: CHRC-002 Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program. Sub-Investigator
- 09/11-2013 Forest: ROFMD07 A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Treated with a Fixed Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Principal Investigator

**RESEARCH:** continued

12/11-2013 Forest: LACMD32 A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Acclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD). Principal Investigator

**ABSTRACT/POSTER PRESENTATIONS:**

- Sept 1999 “Is cardiopulmonary stress testing necessary prior to pulmonary rehabilitation for the purpose of the exercise prescription?”  
N. Pies, M. Zaleskiewicz, A. Miller, R. Benko, A. Rizzo, M.D.  
Christiana Care Health Services  
Presented at AACVPR Annual Meeting, Phoenix, AZ, slide presentation
- Sept 1999 “Contribution of education to quality of life in a comprehensive pulmonary rehabilitation program.”  
A. Miller, N. Pies, M. Zaleskiewicz, A. Rizzo, M.D.  
Christiana Care Health Services  
Presented at AACVPR Annual Meeting, Phoenix, AZ, poster session
- Sept 1999 “Comparison of exercise testing modalities for patient with COPD.”  
M. Zaleskiewicz, N. Pies, R. Benko, D. Sestili, A. Rizzo, M.D.  
Christiana Care Health Services  
Presented at ACCVPR Annual Meeting, Phoenix, AZ, poster session
- 2000 Adopt-a-School Asthma Education Program, Principal Investigator
- 2001 Physician Asthma Care Education (PACE), Regional Leader  
University of Michigan, School of Public Health
- 2003 “Evaluation of the Effectiveness of an Asthma Educational Camp Implemented by Respiratory Care Students Using NIH/NHLBI Guidelines” Tom Blackson BS RRT, Joseph A Ciarlo RRT Robert Lang, BS RRT, Tim Cox BS RRT, Albert Rizzo MD
- 2006 The Role of CPAP treatment in Improving Cardiac Autonomic Neuropathy in Diabetic Patients with Obstructive Sleep Apnea Accepted as Abstract for the American Diabetes Association National meeting
- 2007 Submitted to CHEST for publication: Role of CPAP in Diabetics with OSA
- 2007 The use of the BODE index in evaluating patients with COPD during Pulmonary Rehabilitation presented at AACVPR national meeting Salt Lake City October 2007
- 2018 Patterson, F, Perkett, M., Hernandez, Y., Heath, A., Rizzo, A., Malone, S.K., Edwards, D.G., Grandner, M.A. (2018). *Healthier Sleep as an adjunctive treatment for smoking cessation: A proof of concept study*. Poster presentation, National IDeA Symposium of Biomedical Research Excellence, Washington DC, June 24-26.

## TEACHING RESPONSIBILITIES:

Medical Center of Delaware/Delaware Technical & Community College School of Respiratory Care Medical Director	1998-2018
Medical Advisory Board	1986-2018
Christiana Care Health Services (Formerly Medical Center of Delaware) Daily ICU Rounds	1989-1993
Family Practice Teaching Rounds/Wilmington Hospital Pulmonary Clinic Attending/Wilmington Hospital	1995-2006
Critical Care Attending Physician/Medical Teaching Service Wilmington Hospital	1995-2016
Pulmonary/Critical Care Attending Christiana Hospital	1986-Present
Core Residency Lectures in pulmonary, critical care, sleep medicine	1986-Present
Jefferson Medical College Core lectures to medical students Arterial Blood Gas Workshop	1989-1993
Pike Creek Court and Health Club Medical Advisory Board	1996-1998

## BIBLIOGRAPHY:

Rizzo, AA. "Medical Grand Rounds: The Pickwickian Syndrome"  
Delaware Medical Journal, October 1986

Chabalko, JJ; Rizzo, AA, Lang, LP. "Crab Lung"  
New England Journal of Medicine, 1984; 311: 1703

Blackson, T; Ciarlo J; Rizzo, A.  
"A case of patient-ventilator dyssynchrony caused by inadvertent PEEP"  
Respiratory Care, 1995; 40(11: 1144-1147)  
Maser, Lenhard, Rizzo, Vasile

Maser R; Lenhard, J; Rizzo A; Vasile A; "The Role of CPAP treatment in Improving Cardiac Autonomic Neuropathy in Diabetic Patients with Obstructive Sleep Apnea" CHEST Feb 2008

Sawyer, A. M., King, T. S., Hanlon, A., Richards, K. C., Sweer, L., Rizzo, A., & Weaver, T. E. (2014). "Risk assessment for CPAP nonadherence in adults with newly diagnosed obstructive sleep apnea: preliminary testing of the Index for Nonadherence to PAP (I-NAP)." Sleep & Breathing. doi: <http://dx.doi.org/10.1007/s11325-014-0959-z>

Patterson, F; Grandner M; Malone, S; Rizzo, A; Davey, A; Edwards, D; "Sleep as a Target for Optimized Response to Smoking Cessation Treatment," Nicotine and Tobacco Research, in press. 2017